Skip to main navigation Skip to search Skip to main content

Lazertinib Versus Gefitinib as First-Line Treatment in Patients with EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: Results from LASER301

  • Byoung Chul Cho
  • , Myung Ju Ahn
  • , Jin Hyoung Kang
  • , Ross A. Soo
  • , Thanyanan Reungwetwattana
  • , James Chih Hsin Yang
  • , Irfan Cicin
  • , Dong Wan Kim
  • , Yi Long Wu
  • , Shun Lu
  • , Ki Hyeong Lee
  • , Yong Kek Pang
  • , Anastasia Zimina
  • , Chin Heng Fong
  • , Elena Poddubskaya
  • , Ahmet Sezer
  • , Soon Hin How
  • , Pongwut Danchaivijitr
  • , Yukyung Kim
  • , Yeji Lim
  • Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
  • Yonsei University
  • Samsung Medical Center, Sungkyunkwan university
  • National University Hospital
  • Mahidol University
  • National Taiwan University
  • Trakya University
  • Seoul National University
  • Guangdong Academy of Medical Sciences
  • Shanghai Jiao Tong University
  • Chungbuk National University
  • University of Malaya
  • Omsk Clinical Oncological Dispensary
  • Hospital Pulau Pinang
  • Sechenov First Moscow State Medical University
  • Adana Baskent Practice and Research Hospital
  • Hospital Tengku Ampuan Afzan
  • Yuhan Corporation
  • University of Novi Sad

Research output: Contribution to journalArticlepeer-review

149 Scopus citations

Fingerprint

Dive into the research topics of 'Lazertinib Versus Gefitinib as First-Line Treatment in Patients with EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: Results from LASER301'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science